Allianz Asset Management GmbH Makes New $2.64 Million Investment in Enliven Therapeutics, Inc. $ELVN

Key Points

• Allianz Asset Management initiated a $2.64 million position in Enliven Therapeutics during the second quarter, while institutional investors collectively own 95.08% of the company.
• ELVN shares opened at $59.37, near their 52-week high of $62.32. The company reported a quarterly loss of $0.49 per share, missing analysts’ $0.39 loss estimate.
• Analysts remain broadly bullish, with eight Buy ratings and one Sell rating, a “Moderate Buy” consensus, and an average price target of $75—above the current share price. Meanwhile, insiders sold nearly $11 million of stock over the past 90 days.

Allianz Asset Management GmbH purchased a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 52,008 shares of the company's stock, valued at approximately $2,639,000. Allianz Asset Management GmbH owned about 0.07% of Enliven Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. purchased a new stake in Enliven Therapeutics during the 2nd quarter worth about $221,255,000. California State Teachers Retirement System grew its stake in Enliven Therapeutics by 8,378.2% in the 2nd quarter. California State Teachers Retirement System now owns 2,705,736 shares of the company's stock worth $137,316,000 after acquiring an additional 2,673,822 shares during the period. Vestal Point Capital LP raised its holdings in Enliven Therapeutics by 230.2% in the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company's stock valued at $58,982,000 after acquiring an additional 2,670,000 shares during the last quarter. Siren L.L.C. acquired a new position in Enliven Therapeutics in the 1st quarter valued at $29,252,000. Finally, Jupiter Topco LLC purchased a new position in shares of Enliven Therapeutics during the 2nd quarter worth $30,617,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Stock Up 0.1%

ELVN stock opened at $59.37 on Wednesday. The company has a market cap of $4.35 billion, a price-to-earnings ratio of -35.55 and a beta of 0.30. The business has a fifty day simple moving average of $56.00 and a 200-day simple moving average of $44.77. Enliven Therapeutics, Inc. has a 52 week low of $14.78 and a 52 week high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). As a group, analysts expect that Enliven Therapeutics, Inc. will post -1.69 earnings per share for the current fiscal year.

Insider Buying and Selling at Enliven Therapeutics

In other news, Director Mika K. Derynck sold 158,795 shares of the stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total value of $9,561,046.95. Following the completion of the sale, the director owned 87,373 shares of the company's stock, valued at $5,260,728.33. This represents a 64.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction on Monday, July 6th. The shares were sold at an average price of $50.49, for a total transaction of $504,900.00. Following the transaction, the director owned 41,884 shares in the company, valued at $2,114,723.16. The trade was a 19.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 186,849 shares of company stock valued at $10,998,857 over the last ninety days. Corporate insiders own 3.00% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Guggenheim decreased their price objective on Enliven Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. Stifel Nicolaus upped their target price on Enliven Therapeutics from $80.00 to $82.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Mizuho increased their target price on Enliven Therapeutics from $62.00 to $73.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 18th. William Blair assumed coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an "outperform" rating on the stock. Finally, HC Wainwright lifted their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the company a "buy" rating in a report on Thursday, July 9th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Enliven Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $75.00.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

Want to see what other hedge funds are holding ELVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.